Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study

Neuropsychobiology

Volumn 62, Issue 2, 2010, Pages 81-86

  Lim, Hyun Kook ^a   Kim, Jung Jin ^a   Pae, Chi Un ^a   Lee, Chang Uk ^a   Lee, Chul ^a   Paik, In Ho ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Intramuscular haloperidol; Psychotic agitation; Risperidone orodispersible tablet

Indexed keywords

HALOPERIDOL; LORAZEPAM; RISPERIDONE; NEUROLEPTIC AGENT;

ACUTE DISEASE; ACUTE DYSTONIA; ACUTE PSYCHOSIS; ACUTE PSYCHOTIC AGITATION; ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISPERSIBLE TABLET; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EMERGENCY TREATMENT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GROUP DYNAMICS; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGED; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953018117     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315437     Document Type: Article

References (23)

1. Atakan Z, Davies T: ABC of mental health. Mental health emergencies. BMJ 1997; 314: 1740-1742.
2. Currier GW, Allen M: Organization and function of academic psychiatric emergency services. Gen Hosp Psychiatry 2003; 25: 124-129.
3. Binder RL, McNiel DE: Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999; 50: 1553-1554.
4. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, McGlynn C, Goodman L: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335-340.
5. Currier GW, Trenton A: Pharmacological treatment of psychotic agitation. CNS Drugs 2002; 16: 219-228.
6. Do AN, Ciesielski CA, Metler RP, Hammett TA, Li J, Fleming PL: Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the united states. Infect Control Hosp Epidemiol 2003; 24: 86-96.
7. Kerr IB, Taylor D: Acute disturbed or violent behaviour: Principles of treatment. J Psychopharmacol 1997; 11: 271-277.
8. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP: The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001: 1-88; quiz 89-90.
9. Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R: What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 2003; 9: 39-58.
10. Czobor P, Volavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243-249.
11. Currier GW, Simpson GM: Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62: 153-157.
12. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM: Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65: 386-394.
13. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
14. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, US Department of Health, Education, and Welfare Government Printing Office, Publication (ADM), 1976.
15. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 45: 11-19.
16. Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A: Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry 2006; 39: 209-212.
17. Centorrino F, Meyers AL, Ahl J, Cincotta SL, Zun L, Gulliver AH, Kinon BJ, Houston JP: An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/ schizoaffective disorder. Hum Psychopharmacol 2007; 22: 455-462.
18. Thyssen A, Remmerie B, DHoore P, Kushner S, Mannaert E: Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther 2007; 29: 290-304.
19. Kane JM: Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11(suppl 4):S397-S403.
20. Battaglia J: Pharmacological management of acute agitation. Drugs 2005; 65: 1207-1222.
21. Marder SR: A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006; 67(suppl 10):13-21.
22. Keith S: Advances in psychotropic formulations. Prog Neuropsychophamacol Biol Psychiatry 2006; 30: 996-1008.
23. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E: Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63: 493-512.